NCT01532882已完成3 期
Assessment of the Efficacy and Safety of Diosmin 600mg on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs: a Multicentric, Randomised, Double-blind, Placebo-controlled Trial in Parallel Groups
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 378
- 试验地点
- 1
- 主要终点
- Change of Visual analog Scale score for assessment of the painful venous symptomatology
研究概览
简要总结
Diosmin has a well established use status in improvement of the symptoms of venolymphatic insufficiency: heavy legs, pain, primo-decubitus restlessness and as complement treatment of capillary fragility.
Nevertheless, diosmin 600 mg did not benefit from a rigorous clinical study versus placebo, to establish its efficacy in the pain relief in Chronic Venous Disease (CVD).
The aim of this project led by Dr. Guex is to evaluate the efficacy and safety of diosmin 600 mg - DIOVENOR® on the painful symptoms of CVD of the lower limbs, in a multicentre, controlled, randomised, double blind, placebo-controlled, parallel-group study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient, man or woman, aged 18 and over,
- •Patient presenting a C1s or C2s venous disease grade of the lower limbs
- •Patient presenting a painful venous symptomatology in the lower limbs for at least 15 days.
- •Patient suffering from venous symptomatology in one leg with a painful symptom intensity higher or equal to 30 mm (VAS= 100mm)
排除标准
- •Patient treated by venotonic treatments or vascular protectants or assimilated dietary supplements or homeopathic treatments or diuretics within 15 days prior inclusion,
- •Patients who started treatments such as calcium inhibitors, beta-blockers, angiotensin converting enzyme inhibitors and/or vasodilators and/or vasoconstrictors within 28 days prior inclusion (for patients already taking this type of treatments, dosage should not have been changed in the 28 days prior inclusion and should not be planned to change in the course of the study),
- •Patient treated by any analgesic within 7 days prior inclusion,
- •Patient treated by an anti-inflammatory treatment within 7 days prior inclusion,
- •Patient using elastic venous compression
- •Patient presenting permanent oedema,
- •Patients presenting venous skin changes,
- •Patient whose activity in the 4 following weeks (that is to say during the study) would be different from his/her usual activities (before the study),
- •Patient suffering from a pathology generating other pains than venous pains in the lower limbs,
- •Patient with a history of lower limbs trauma responsible for sequel pains,
- •Patient with a known deep venous reflux,
- •Patient with a history of venous thromboses or thrombo-embolic diseases within the last 6 months before inclusion,
- •Patient treated with analgesics or anti-inflammatory treatments used as analgesics within 4 weeks prior inclusion
- •Patient having a known hypersensitivity to diosmin or one of the excipients
- •Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption ),
研究组 & 干预措施
Diosmin
Experimental
干预措施: Diosmin (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change of Visual analog Scale score for assessment of the painful venous symptomatology
时间窗: baseline and after 28 days
次要结局
- - Painful symptom intensity (daily VAS score) Area Under the Curve(28 days)
- - Daily VAS score for Response rate(28 days)
- - Daily VAS score for Time to response(28 days)
- - Score of Quality of life questionnaire (SQOR-V)(Between baseline and 28 days)
- - Patient's and physician's global satisfaction score(At 28 days)
- Adverse Events (numbers and frequency)(28 days)
- - Unusual intakes of analgesic treatments (rate of patients)(28 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Effect of Intravenous vitamin c in Patients with COVID-19IRCT20200411047025N1Tehran University of Medical Sciences110
尚未招募
4 期
Comparison of intravenous dexmedetomidine and low dose ketamine to prevent shivering in spinal anaesthesiaCTRI/2021/08/035439Department of anaesthesiology
招募中
1 期
Evaluation of the efficacy of intra venous dornase alfa (Pulmozyme®) on arterial recanalization in post-thrombectomy angiography in patients managed for ischemic stroke with thrombolysis and eligible for thrombectomy: a single-center phase II trial.Ischemic strokeMedDRA version: 22.1Level: LLTClassification code: 10055221Term: Ischemic stroke Class: 10029205CTIS2024-515831-31-00Fondation A De Rothschild44
尚未招募
Unknown
Efficacy of dexmedetomidine drug in addition to muscle block for pain relief in spine surgeryCTRI/2023/04/051398Department of Anaesthesia and Intensive Care
尚未招募
不适用
Check efficacy of intravenous lidocaine for analgesia in post operative period.CTRI/2020/09/027564INDIRA GANDHI INSTITUTE OF MEDICAL SCIENCES